Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Faez Iqbal Khan, Dakun Lai, Razique Anwer, Iffat Azim & Mohd Kalim Ahmad Khan. (2020) Identifying novel sphingosine kinase 1 inhibitors as therapeutics against breast cancer. Journal of Enzyme Inhibition and Medicinal Chemistry 35:1, pages 172-186.
Read now
Read now
Articles from other publishers (52)
Ehab S EL Desoky, Amira F Taha, Heba Salah Mousa, Abeer Ibrahim, Medhat A Saleh, Mohamed A Abdelrady & Mohammad Salem Hareedy. (2022) Value of therapeutic drug monitoring of endoxifen in Egyptian premenopausal patients with breast cancer given tamoxifen adjuvant therapy: A pilot study. Journal of Oncology Pharmacy Practice 29:7, pages 1673-1686.
Crossref
Crossref
Bianza Tinotenda Mbavha, Roslyn Stella Thelingwani, Zedias Chikwambi, Anna Mary Nyakabau & Collen Masimirembwa. (2023) Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort. British Journal of Clinical Pharmacology 89:10, pages 3209-3216.
Crossref
Crossref
Ekaterina Olegovna Golubenko, Marina Ivanovna Savelyeva, Zhannet Alimovna Sozaeva, Vera Vyacheslavovna Korennaya, Irina Vladimirovna Poddubnaya, Timur Tejmurazovich Valiev, Svetlana Nikolaevna Kondratenko & Mikhail Vitalyevich Ilyin. (2023) Predictive modeling of adverse drug reactions to tamoxifen therapy for breast cancer on base of pharmacogenomic testing. Drug Metabolism and Personalized Therapy 0:0.
Crossref
Crossref
Shingirai M. Chiwambutsa, Oluwatosin Ayeni, Nyasha Kapungu, Comfort Kanji, Roslyn Thelingwani, Wenlong Carl Chen, Dikeledi H. Mokone, Daniel S. O'Neil, Alfred I. Neugut, Judith S. Jacobson, Paul Ruff, Herbert Cubasch, Maureen Joffe & Collen Masimirembwa. (2023) Effects of Genetic Polymorphisms of Drug Metabolizing Enzymes and co‐Medications on Tamoxifen Metabolism in Black South African Women with Breast Cancer. Clinical Pharmacology & Therapeutics 114:1, pages 127-136.
Crossref
Crossref
Song Ah Chae, Min Du, Jun Seok Son & Mei‐Jun Zhu. (2023) Exercise improves homeostasis of the intestinal epithelium by activation of apelin receptor–AMP‐activated protein kinase signalling. The Journal of Physiology 601:12, pages 2371-2389.
Crossref
Crossref
E. T. D. Souwer, A. Sanchez-Spitman, D. J. A. R. Moes, H. Gelderblom, J. J. Swen, J. E. A. Portielje, H. J. Guchelaar & T. van Gelder. (2023) Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer. Breast Cancer Research and Treatment 199:3, pages 471-478.
Crossref
Crossref
E. O. Golubenko, M. I. Savelyeva, Z. A. Sozaeva, I. V. Poddubnaya & V. V. Korennaya. (2023) Predictive modeling of adverse events of tamoxifen therapy for breast cancer (results of a cohort study). Pharmacogenetics and Pharmacogenomics:1, pages 63-73.
Crossref
Crossref
Ya-Lin Huang, Cristian De Gregorio, Verónica Silva, Álvaro A. Elorza, Patricio Léniz, Víctor Aliaga-Tobar, Vinicius Maracaja-Coutinho, Mauricio Budini, Fernando Ezquer & Marcelo Ezquer. (2023) Administration of Secretome Derived from Human Mesenchymal Stem Cells Induces Hepatoprotective Effects in Models of Idiosyncratic Drug-Induced Liver Injury Caused by Amiodarone or Tamoxifen. Cells 12:4, pages 636.
Crossref
Crossref
Comfort Ropafadzo Kanji, Georginah Nyabadza, Charles Nhachi & Collen Masimirembwa. (2023) Pharmacokinetics of Tamoxifen and Its Major Metabolites and the Effect of the African Ancestry Specific CYP2D6*17 Variant on the Formation of the Active Metabolite, Endoxifen. Journal of Personalized Medicine 13:2, pages 272.
Crossref
Crossref
Denise N. Keller, Samantha J. Medwid, Cameron D. Ross, Theodore J. Wigle & Richard B. Kim. (2022) Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects. Pharmacogenetics and Genomics 33:1, pages 10-18.
Crossref
Crossref
Jaya Dilli Batcha, Arun Raju, Saikumar Matcha, Elstin Raj S.Karthik Udupa, Vikram Gota & Surulivelrajan Mallayasamy. (2022) Factors Influencing Pharmacokinetics of Tamoxifen in Breast Cancer Patients: A Systematic Review of Population Pharmacokinetic Models. Biology 12:1, pages 51.
Crossref
Crossref
Samantha Medwid & Richard B. Kim. (2022) Implementation of pharmacogenomics: Where are we now?. British Journal of Clinical Pharmacology.
Crossref
Crossref
Wouroud Ismail Al-khalil, Lana Al-Salhi, Sara Rijjal, Majd Aljamali & Lama A. Youssef. (2022) The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients. BMC Cancer 22:1.
Crossref
Crossref
Emily J. Koubek, Andrew T. Ralya, Thomas R. Larson, Renee M. McGovern, Sarah A. Buhrow, Joseph M. Covey, Alex A. Adjei, Naoko Takebe, Matthew M. Ames, Matthew P. Goetz & Joel M. Reid. (2022) Population Pharmacokinetics of Z‐Endoxifen in Patients With Advanced Solid Tumors. The Journal of Clinical Pharmacology 62:9, pages 1121-1131.
Crossref
Crossref
Miriam MoralesSilvia Romano, Angélica Aguilar, Susanna Medellín, Rosa Milán, José Cruz, José Zermeño & Alejandra Segarra. (2022) Factors Associated with Plasma Levels of Tamoxifen and its Main
Metabolites in Mexican Patients with Breast Cancer. Current Pharmacogenomics and Personalized Medicine 19:2, pages 86-99.
Crossref
Crossref
C. Louwrens Braal, Justin D. Westenberg, Sanne M. Buijs, Steven Abrams, Tessa A. M. Mulder, Ron H. N. van Schaik, Stijn L. W. Koolen, Agnes Jager & Ron H. J. Mathijssen. (2022) Factors affecting inter-individual variability in endoxifen concentrations in patients with breast cancer: results from the prospective TOTAM trial. Breast Cancer Research and Treatment 195:1, pages 65-74.
Crossref
Crossref
Mitra Khodaei, Soghra Mehri, Soroush Rashid Pour, Shakiba Mahdavi, Fatemeh Yarmohammadi, A. Wallace Hayes & Gholamreza Karimi. (2022) The protective effect of chemical and natural compounds against vincristine-induced peripheral neuropathy (VIPN). Naunyn-Schmiedeberg's Archives of Pharmacology 395:8, pages 907-919.
Crossref
Crossref
Danilo Giffoni de Mello Morais Mata, Carlos Amir Carmona, Andrea Eisen & Maureen Trudeau. (2022) Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer—A Literature Review. Current Oncology 29:7, pages 4956-4969.
Crossref
Crossref
Sinziana Ionescu, Alin Codrut Nicolescu, Marian Marincas, Octavia-Luciana Madge & Laurentiu Simion. (2022) An Update on the General Features of Breast Cancer in Male Patients—A Literature Review. Diagnostics 12:7, pages 1554.
Crossref
Crossref
C. Louwrens Braal, Agnes Jager, Esther Oomen-de Hoop, Justin D. Westenberg, Koen M. W. T. Lommen, Peter de Bruijn, Mijntje B. Vastbinder, Quirine C. van Rossum-Schornagel, Martine F. Thijs-Visser, Robbert J. van Alphen, Liesbeth E. M. Struik, Hanneke J. M. Zuetenhorst, Ron H. J. Mathijssen & Stijn L. W. Koolen. (2021) Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer. Clinical Pharmacokinetics 61:4, pages 527-537.
Crossref
Crossref
Carine M. Abdelmalek, Zexi Hu, Thales Kronenberger, Jenni Küblbeck, Franziska J. M. Kinnen, Salma S. Hesse, Afsin Malik, Mark Kudolo, Raimund Niess, Matthias Gehringer, Lars Zender, Paula A. Witt-Enderby, Darius P. Zlotos & Stefan A. Laufer. (2022) Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer. Journal of Medicinal Chemistry 65:6, pages 4616-4632.
Crossref
Crossref
Yung-Yi Cheng, Teresa Zheng, Michael W. Chang, Jeffrey W. Dalley, Yu-Jen Chen, Tung-Hu Tsai & Chen-Hsi Hsieh. (2022) Impact of Irradiation on the Pharmacokinetics and Biotransformation of Tamoxifen. Frontiers in Oncology 12.
Crossref
Crossref
Sara M. Tolaney, Muralidhar Beeram, J. Thaddeus Beck, Alison Conlin, E. Claire Dees, Shannon L. Puhalla, Brent N. Rexer, Howard A. Burris3rd3rd, Komal Jhaveri, Teresa Helsten, Carlos Becerra, Kevin Kalinsky, Kathleen N. Moore, Allison M. Manuel, Andrew Lithio, Gregory L. Price, Sonya C. Chapman, Lacey M. Litchfield & Matthew P. Goetz. (2022) Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study. Frontiers in Oncology 11.
Crossref
Crossref
C. Louwrens Braal, Anne Kleijburg, Agnes Jager, Stijn L. W. Koolen, Ron H. J. Mathijssen, Isaac Corro Ramos, Pim Wetzelaer & Carin A. Uyl-de Groot. (2022) Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial. Clinical Drug Investigation 42:2, pages 163-175.
Crossref
Crossref
Kiminori Ohta, Asako Kaise, Takumi Ogawa & Yasuyuki Endo. (2022) Challenging Approach to the Development of Novel Estrogen Receptor Modulators Based on the Chemical Properties of Guaiazulene. International Journal of Molecular Sciences 23:3, pages 1113.
Crossref
Crossref
Douglas C. Brandão, Paula M. A. P. Lima, Isabella C. Martins, Carina S. Cordeiro, Antonielle O. Cordeiro, Lara Vecchi, Joyce F. C. Guerra, Priscila C. Orsolin, Matheus C. Gazolla, Danilo S. Costa, Ademar A. da Silva Filho & Thaise G. Araújo. (2022) Arrabidaea chica chloroform extract modulates estrogen and androgen receptors on luminal breast cancer cells. BMC Complementary Medicine and Therapies 22:1.
Crossref
Crossref
Stefan A. J. Buck, C. Louwrens Braal, Maaike M. Hofman, Esther Oomen-de Hoop, Peter de Bruijn, Inge M. Ghobadi Moghaddam-Helmantel, Koen G. A. M. Hussaarts, Mijntje B. Vastbinder, Quirine C. van Rossum-Schornagel, Ron H. N. van Schaik, Agnes Jager, Stijn L. W. Koolen & Ron H. J. Mathijssen. (2022) Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment. Therapeutic Advances in Medical Oncology 14, pages 175883592210810.
Crossref
Crossref
Swaathi Jayaraman, Joel M Reid, John R Hawse & Matthew P Goetz. (2021) Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside. Endocrinology 162:12.
Crossref
Crossref
Eleonora Nicolò, Dario Trapani, Pier Paolo Maria Berton Giachetti, Paola Zagami & Giuseppe Curigliano. (2021) Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations. Cancer Treatment Reviews 100, pages 102281.
Crossref
Crossref
Marcos Antonio Villetti, Adryana Rocha Clementino, Ilaria Dotti, Patricia Regina Ebani, Eride Quarta, Francesca Buttini, Fabio Sonvico, Annalisa Bianchera & Redouane Borsali. (2021) Design and Characterization of Maltoheptaose-b-Polystyrene Nanoparticles, as a Potential New Nanocarrier for Oral Delivery of Tamoxifen. Molecules 26:21, pages 6507.
Crossref
Crossref
Maria Lucia Souza Siqueira, Sara Michelli Vieira Andrade, José Luiz Fernandes Vieira & Marta Chagas Monteiro. (2021) A preliminary study on the association of tamoxifen, endoxifen, and 4-hydroxytamoxifen with blood lipids in patients with breast cancer. Biomedicine & Pharmacotherapy 142, pages 111972.
Crossref
Crossref
Sebanti Ganguly, Itika Arora & Trygve O. Tollefsbol. (2021) Impact of Stilbenes as Epigenetic Modulators of Breast Cancer Risk and Associated Biomarkers. International Journal of Molecular Sciences 22:18, pages 10033.
Crossref
Crossref
Maaike van der Lee, William G. AllardRolf H. A. M. VossenRenée F. Baak-PabloRoberta Menafra, Birgit A. L. M. Deiman, Maarten J. Deenen, Patrick NevenInger JohanssonStefano Gastaldello, Magnus Ingelman-SundbergHenk-Jan Guchelaar, Jesse J. Swen & Seyed Yahya Anvar. (2021)
Toward predicting CYP2D6-mediated variable drug response from
CYP2D6
gene sequencing data
. Science Translational Medicine 13:603.
Crossref
Crossref
Yasmin Cura, Cristina Pérez Ramírez, Almudena Sánchez Martín, Fernando Martínez Martínez, Miguel Ángel Calleja Hernández, María del Carmen Ramírez Tortosa & Alberto Jiménez Morales. (2021) Genetic polymorphisms on the effectiveness or safety of breast cancer treatment: Clinical relevance and future perspectives. Mutation Research/Reviews in Mutation Research 788, pages 108391.
Crossref
Crossref
Yuanhuang Chen, Lauren A. Marcath, Finn Magnus Eliassen, Tone Hoel Lende, Havard Soiland, Gunnar Mellgren, Thomas Helland & Daniel Louis Hertz. (2021) Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites. Journal of Personalized Medicine 11:6, pages 507.
Crossref
Crossref
Deborah Molehin, Fahmida Rasha, Rakhshanda Layeequr Rahman & Kevin Pruitt. (2021) Regulation of aromatase in cancer. Molecular and Cellular Biochemistry 476:6, pages 2449-2464.
Crossref
Crossref
Anna Mueller-Schoell, Robin Michelet, Lena Klopp-Schulze, Madelé van Dyk, Thomas E. Mürdter, Matthias Schwab, Markus Joerger, Wilhelm Huisinga, Gerd Mikus & Charlotte Kloft. (2021) Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups. Cancers 13:10, pages 2432.
Crossref
Crossref
Simona Saponara, Fabio Fusi, Daniele Iovinelli, Amer Ahmed, Alfonso Trezza, Ottavia Spiga, Giampietro Sgaragli & Massimo Valoti. (2021) Flavonoids and hERG channels: Friends or foes?. European Journal of Pharmacology 899, pages 174030.
Crossref
Crossref
Narayan D. Chaurasiya, Haining Liu, Robert J. Doerksen, N. P. Dhammika Nanayakkara, Larry A. Walker & Babu L. Tekwani. (2021) Enantioselective Interactions of Anti-Infective 8-Aminoquinoline Therapeutics with Human Monoamine Oxidases A and B. Pharmaceuticals 14:5, pages 398.
Crossref
Crossref
Thomas Helland, Sarah Alsomairy, Chenchia Lin, Håvard Søiland, Gunnar Mellgren & Daniel Louis Hertz. (2021) Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer. Journal of Personalized Medicine 11:3, pages 201.
Crossref
Crossref
Quan He, Cuirong Sun, Jian Liu & Yuanjiang Pan. (2021) MALDI-MSI analysis of cancer drugs: Significance, advances, and applications. TrAC Trends in Analytical Chemistry 136, pages 116183.
Crossref
Crossref
Anna Mueller-Schoell, Lena Klopp-Schulze, Robin Michelet, Madelé van Dyk, Thomas E. Mürdter, Matthias Schwab, Markus Joerger, Wilhelm Huisinga, Gerd Mikus & Charlotte Kloft. (2021) Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies. Pharmaceuticals 14:2, pages 115.
Crossref
Crossref
Madhurendra Singh, Xiaolei Zhou, Xinsong Chen, Gema Sanz Santos, Sylvain Peuget, Qing Cheng, Ali Rihani, Elias S. J. Arnér, Johan Hartman & Galina Selivanova. (2020) Identification and targeting of selective vulnerability rendered by tamoxifen resistance. Breast Cancer Research 22:1.
Crossref
Crossref
Sudesh Rani & Kamaldeep Paul. (2020) Triphenylethylene analogues: Design, synthesis and evaluation of antitumor activity and topoisomerase inhibitors. European Journal of Medicinal Chemistry 208, pages 112775.
Crossref
Crossref
Haiyan Liang, Bin Hu, Lei Chen, Shuaiqun Wang & Aorigele. (2020) Recognizing novel chemicals/drugs for anatomical therapeutic chemical classes with a heat diffusion algorithm. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1866:11, pages 165910.
Crossref
Crossref
Anna Mueller‐Schoell, Lena Klopp‐Schulze, Werner Schroth, Thomas Mürdter, Robin Michelet, Hiltrud Brauch, Wilhelm Huisinga, Markus Joerger, Patrick Neven, Stijn L.W. Koolen, Ron H.J. Mathijssen, Ellen Copson, Diana Eccles, Sylvia Chen, Balram Chowbay, Arafat Tfayli, Nathalie K. Zgheib, Matthias Schwab & Charlotte Kloft. (2020) Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach. Clinical Pharmacology & Therapeutics 108:3, pages 661-670.
Crossref
Crossref
Carolyn E. Kezar, Leslie K. Dawson, Gabrielle B. Rocque & Keith M. Swetz. (2020) Heightened Tamoxifen Activation Masquerading as a Venlafaxine-Associated Adverse Event After Rotation From Duloxetine. Journal of Pain and Symptom Management 60:2, pages e104-e106.
Crossref
Crossref
Carmen W. H. Chan, Bernard M. H. Law, Winnie K. W. So, Ka Ming Chow & Mary M. Y. Waye. (2020) Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen. Journal of Cancer Research and Clinical Oncology 146:6, pages 1395-1404.
Crossref
Crossref
Anabel Beatriz Sanchez-Spitman, Dirk-Jan A. R. Moes, Jesse J. Swen, Vincent O. Dezentjé, Diether Lambrechts, Patrick Neven, Hans Gelderblom & Henk-Jan Guchelaar. (2020) Exposure–response analysis of endoxifen serum concentrations in early-breast cancer. Cancer Chemotherapy and Pharmacology 85:6, pages 1141-1152.
Crossref
Crossref
Zeina N. Al-Mahayri, George P. Patrinos & Bassam R. Ali. (2020) Toxicity and Pharmacogenomic Biomarkers in Breast Cancer Chemotherapy. Frontiers in Pharmacology 11.
Crossref
Crossref
Azher Arafah, Khalid Yakout, Muneeb U. Rehman, Ammar Mohammed Alsharif, Mohammad H. AlJawadi & Hussain Abdulrahman Al-Omar. (2020) Prevalence of the co-prescription of tamoxifen and CYP2D6 inhibitors in Saudi population: A cross sectional study. Saudi Pharmaceutical Journal 28:4, pages 440-444.
Crossref
Crossref
Sara S. Reis, Ana S. Carvalho & Rúben Fernandes. (2019) Pharmacogenomics, CYP2D6, and Tamoxifen: A Survey of the Reasons Sustaining European Clinical Practice Paradigms. Medicina 55:7, pages 344.
Crossref
Crossref